Physician profile
Kunwardeep S Sohal
NPI 1043416407
$2,860.89
in general payments reported to CMS, 2019-2025
21 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $432 · 2023: $925 · 2024: $1,335 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.35 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $382.23 | 2022-2025 | |
| Abbvie INC. | $347.44 | 2023-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $343.00 | 2022-2024 | Stelara, Simponi, Remicade |
| Qol Medical, LLC | $291.17 | 2022-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $230.58 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.15 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $174.39 | 2022-2024 | |
| Ardelyx, INC. | $159.20 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $155.26 | 2022-2024 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $124.08 | 2022-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $97.54 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $68.49 | 2022-2024 | Dificid, Zinplava |
| Celgene Corporation | $52.91 | 2022-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $46.96 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $44.26 | 2023-2024 | Sutab, Suflave |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $37.67 | 2024 | Pertzye |
| Ipsen Biopharmaceuticals, INC | $24.18 | 2024 | Iqirvo |
| Organon LLC | $22.55 | 2023 | Renflexis, Hadlima |
| Nestle Healthcare Nutrition INC. | $21.62 | 2023 | |
| Pfizer INC. | $18.02 | 2024 | |
| Boston Scientific Corporation | $13.19 | 2024 | Resolution Clip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunwardeep Sohal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.